glp-1 medications approved for type 2 diabetes 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with ADA 2025: Advances in Type

The Influence and Mechanism of GLP-1 RAs in Modulating Hypertension Hypertension, a chronic cardiovascular disease, affects a large number of individuals, with its prevalence increasing, making it a major cause of mortality and disability [72]

Furthermore, 86% of the participants treated with semaglutide achieved a weight loss of 5% or more, and 69% achieved a weight loss of 10% or more

10.3390/toxics13070594 14 EngstrmA.WintzellV.MelbyeM.SvanstrmH.EliassonB.GudbjrnsdottirS.et al (2024)

These fiber supplements can be taken with or without food for convenient daily use

10.1073/pnas.1911464116 80

And thats what we care about and we need to take care of our patients